Chime boosts healthcare offer with De Facto deal

Lord Bell’s Chime Communications has bought biotech PR specialist De Facto Communi- cations in a bid to gain ground in the lucrative healthcare market.

De Facto has Roche, GlaxoSmithKline, Amgen, Johnson & Johnson and Smiths Medical as clients. It handles mainly corporate PR for biotechs, as well as clinical trials marketing and medical education work.

The CEO at 20-strong De Facto – which will relocate from London Bridge to Chime's Holborn offices – is Richard Anderson. Chime's sole current healthcare agency is Ozone, whose staff are now set to relocate from Chelsea to Holborn.

Chime chairman Lord Bell said: 'This acquisition extends our involvement in health and is highly complementary to Ozone.'

Chime already held a 40 per cent share in De Facto – acquired in two stages in December last year and March. The remaining 60 per cent of shares are now being purchased for an initial cash consideration of £219,000.

Deferred payments will be made up to a maximum total consideration of £2m based on De Facto's pre-tax profits over the next four years.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in